Stuttgart - Delayed Quote EUR

Creo Medical Group PLC (1RC.SG)

Compare
0.1100
+0.0010
+(0.92%)
As of 10:55:30 AM GMT+2. Market Open.
Loading Chart for 1RC.SG
  • Previous Close 0.1090
  • Open 0.1110
  • Bid 0.1050 x --
  • Ask 0.1190 x --
  • Day's Range 0.1100 - 0.1110
  • 52 Week Range 0.1090 - 0.4220
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 49.086M
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date May 13, 2025 - May 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the gastrointestinal (GI) tract; ScopeClip for clip placement in the digestive tract; ScopeInject for endoscopic injection into GI mucosa; ScoprGrasp, a disposable grasping forceps for digestive and bronchial endoscopy; ScopeBite, a portfolio of digestive biopsy forceps; and other products for gastroenterology, pulmonology, and urology. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

www.creomedical.com

278

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1RC.SG

View More

Performance Overview: 1RC.SG

Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

1RC.SG
53.78%
FTSE 100 (^FTSE)
3.18%

1-Year Return

1RC.SG
73.56%
FTSE 100 (^FTSE)
0.60%

3-Year Return

1RC.SG
90.55%
FTSE 100 (^FTSE)
3.18%

5-Year Return

1RC.SG
91.29%
FTSE 100 (^FTSE)
35.44%

Compare To: 1RC.SG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1RC.SG

View More

Valuation Measures

Annual
As of 4/9/2025
  • Market Cap

    48.64M

  • Enterprise Value

    53.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.11

  • Price/Book (mrq)

    0.81

  • Enterprise Value/Revenue

    1.52

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -73.93%

  • Return on Assets (ttm)

    -20.09%

  • Return on Equity (ttm)

    -38.49%

  • Revenue (ttm)

    30.3M

  • Net Income Avi to Common (ttm)

    -22.4M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.8M

  • Total Debt/Equity (mrq)

    29.96%

  • Levered Free Cash Flow (ttm)

    -14.95M

Research Analysis: 1RC.SG

View More

Company Insights: 1RC.SG

Research Reports: 1RC.SG

View More

People Also Watch